《慢性乙型肝炎防治指南(2022年版)》修订过程中关于慢性HBV感染自然史的讨论

庄辉

doi:10.3969/j.issn.1001-5256.2023.06.006

《慢性乙型肝炎防治指南(2022年版)》修订过程中关于慢性HBV感染自然史的讨论

DOI: 10.3969/j.issn.1001-5256.2023.06.006

庄辉^, ,

北京大学医学部病原生物学系和感染病中心，北京 100191

利益冲突声明：本文不存在任何利益冲突。

详细信息

通信作者:
庄辉，zhuanghuibmu@163.com (ORCID: 0000-0001-9119-6325)

计量
- 文章访问数: 619
- HTML全文浏览量: 72
- PDF下载量: 210
- 被引次数: 0
出版历程
- 收稿日期: 2023-04-17
- 录用日期: 2023-05-01
- 出版日期: 2023-06-20

Debates on the natural history of chronic hepatitis B virus infection during the update of Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Version)

Hui ZHUANG^{,
,}

Department of Microbiology and Center of Infectious Diseases, Peking University Health Science Center, Beijing 100191, China

More Information

Corresponding author: ZHUANG Hui, zhuanghuibmu@163.com (ORCID: 0000-0001-9119-6325)

摘要

摘要: 本文介绍了《慢性乙型肝炎防治指南(2022年版)》修订过程中关于慢性HBV感染自然史的讨论，包括命名和定义；HBV感染；免疫耐受期患者的HBV DNA阈值；不确定期与自然史；临床诊断与自然史；非活动期患者的HBV DNA阈值。
- 乙型肝炎, 慢性 /
- 乙型肝炎病毒 /
- 感染 /
- 自然史 /
- 不确定期
Abstract: This article introduces the debates on the natural history of chronic hepatitis B virus (HBV) infection during the update of Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Version), including nomenclature and definition, HBV infection, HBV DNA threshold for patients in the immune-tolerant phase, indeterminate phase and natural history, clinical diagnosis and natural history, and HBV DNA threshold for patients in the inactive phase.
- Hepatitis B, Chronic /
- Hepatitis B virus /
- Infections /
- Natural History /
- Indeterminate Phase

HTML全文

表 1 慢性HBV感染自然病程分期^[1]

Table 1. Phases of the natural course of chronic HBV infection^[1]

项目	免疫耐受期 (慢性HBV携带状态)	免疫清除期 (HBeAg阳性CHB)	免疫控制期(非活动性 HBsAg携带状态)	再活动期 (HBeAg阴性CHB)
HBV血清学标志物
HBsAg(IU/mL)	＞1×10⁴	+	＜1×10³	+
抗-HBs	-	-	-	-
HBeAg	+	+	-	+/-
抗-HBe	-	-	+	+/-
抗-HBc	+	+	+	+
HBV DNA(IU/mL)	＞2×10⁷	＞2×10⁴	＜2×10³	≥2×10³
ALT	正常	持续或反复升高	正常	持续或反复升高
肝脏病理学	无明显炎症坏死和纤维化	有明显炎症坏死和/或纤维化	无或仅有轻度炎症，可有不同程度的纤维化	有明显炎症坏死和/或纤维化

下载: 导出CSV

表 2 各国指南界定的“免疫耐受期”HBV DNA水平

Table 2. HBV DNA threshols for the immune tolerant phase recommended by international guidelines

指南	HBV DNA水平
美国临床胃肠病肝病学会2015	高水平(＞20 000 IU/mL)
美国肝病学会2018	很高(典型＞10⁶ IU/mL)
欧洲肝病学会2017	＞10⁷ IU/mL
亚太肝病学会2015	2×10⁷ IU/mL
瑞典抗病毒治疗专家组2020	高水平(＞10⁷ IU/mL)
印度肝病学会2018	＞10⁷ IU/mL
中国台湾肝病学会2019	无数据
沙特肝病和移植学会2021	高水平(＞10⁷ IU/mL)
韩国肝病学会2022	一般≥10⁷ IU/mL

下载: 导出CSV

表 3 各国指南建议HBeAg阴性慢性HBV感染(非活动期、免疫控制期) 的HBV DNA水平

Table 3. HBV DNA thresholds for the HBeAg negative chronic HBV infection (inactive or immune control phase) recommended by international guidelines

指南	HBV DNA水平
亚太肝病学会2015	＜2 000 IU/mL
欧洲肝病学会2017	＜2 000 IU/mL
美国肝病学会2018	＜2 000 IU/mL
印度肝病学会2018	＜2 000 IU/mL
瑞典肝病学会2020	＜2 000 IU/mL
沙特肝病和移植学会2020	＜2 000 IU/mL
美国临床胃肠病肝病学会2021	＜2 000 IU/mL
韩国肝病学会2022	＜2 000 IU/mL
Dusheiko G 2023	＜2 000 IU/mL

下载: 导出CSV

参考文献(28)

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[3]	ABAALKHAIL FA, AL-HAMOUDI WK, KHATHLAN A, et al. SASLT practice guidelines for the management of Hepatitis B virus - An update[J]. Saudi J Gastroenterol, 2021, 27(3): 115-126. DOI: 10.4103/sjg.sjg_539_20.
[4]	MARTIN P, NGUYEN MH, DIETERICH DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 Update[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1766-1775. DOI: 10.1016/j.cgh.2021.07.036.
[5]	HOWELL J, HELLARD M. Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune-tolerant hepatitis B infection[J]. Hepatology, 2022, 76(3): 554-557. DOI: 10.1002/hep.32450.
[6]	DUSHEIKO G, AGARWAL K, MAINI MK. New Approaches to chronic hepatitis B[J]. N Engl J Med, 2023, 388(1): 55-69. DOI: 10.1056/NEJMra2211764.
[7]	JENG WJ, PAPATHEODORIDIS GV, LOK A. Hepatitis B[J]. Lancet, 2023, 401(10381): 1039-1052. DOI: 10.1016/S0140-6736(22)01468-4.
[8]	BERTOLETTI A, KENNEDY PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept[J]. Cell Mol Immunol, 2015, 12(3): 258-263. DOI: 10.1038/cmi.2014.79.
[9]	MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998. DOI: 10.1053/j.gastro.2016.07.012.
[10]	RUAN P, DAI X, SUN J, et al. Different types of viral-host junction found in HBV integration breakpoints in HBV-infected patients[J]. Mol Med Rep, 2019, 19(2): 1410-1416. DOI: 10.3892/mmr.2018.9709.
[11]	KOFFAS A, KUMAR M, GILL US, et al. Chronic hepatitis B: the demise of the 'inactive carrier' phase[J]. Hepatol Int, 2021, 15(2): 290-300. DOI: 10.1007/s12072-021-10137-2.
[12]	NGUYEN MH, GARCIA RT, TRINH HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels[J]. Am J Gastroenterol, 2009, 104(9): 2206-2213. DOI: 10.1038/ajg.2009.248.
[13]	GONG X, YANG J, TANG J, et al. A mechanistic assessment of the discordance between normal serum alanine aminotransferase levels and altered liver histology in chronic hepatitis B[J]. PLoS One, 2015, 10(7): e0134532. DOI: 10.1371/journal.pone.0134532.
[14]	National Health Commission of the People's Republic of China. Diagnosis for HIV/AIDS[S]. 2019-01-02. 中华人民共和国国家卫生健康委员会. 艾滋病和艾滋病毒感染诊断[S]. 2019-01-02.
[15]	CASTRO KG, WARD JW, SLUTSKER L, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults[J]. MMWR Recomm Rep, 1992, 41(RR-17): 1-19.
[16]	HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724.
[17]	MARTIN P, LAU DT, NGUYEN MH, et al. A Treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 Update[J]. Clin Gastroenterol Hepatol, 2015, 13(12): 2071-2087. e16. DOI: 10.1016/j.cgh.2015.07.007.
[18]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[19]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[20]	WESTIN J, ALEMAN S, CASTEDAL M, et al. Management of hepatitis B virus infection, updated Swedish guidelines[J]. Infect Dis (Lond), 2020, 52(1): 1-22. DOI: 10.1080/23744235.2019.1675903.
[21]	ARORA A, SINGH SP, KUMAR A, et al. INASL position statements on prevention, diagnosis and management of hepatitis B virus infection in India: The Andaman Statements[J]. J Clin Exp Hepatol, 2018, 8(1): 58-80. DOI: 10.1016/j.jceh.2017.12.001.
[22]	CHIEN RN, KAO JH, PENG CY, et al. Taiwan consensus statement on the management of chronic hepatitis B[J]. J Formos Med Assoc, 2019, 118(1 Pt 1): 7-38. DOI: 10.1016/j.jfma.2018.11.008.
[23]	Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B[J]. Clin Mol Hepatol, 2022, 28(2): 276-331. DOI: 10.3350/cmh.2021.0178.
[24]	HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1803-1812. e5. DOI: 10.1016/j.cgh.2021.01.019.
[25]	YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
[26]	ZHUANG H. Should chronic hepatitis B in the indeterminate phase be treated?[J]. J Clin Hepatol, 2021, 37(9): 2033-2036. DOI: 10.3969/j.issn.1001-5256.2021.09.007. 庄辉. 不确定期慢性乙型肝炎应否治疗?[J] 临床肝胆病杂志, 2021, 37(9): 2033-2036. DOI: 10.3969/j.issn.1001-5256.2021.09.007.
[27]	SPRADLING PR, XING J, RUPP LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013[J]. Aliment Pharmacol Ther, 2016, 44(10): 1080-1089. DOI: 10.1111/apt.13802.
[28]	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)[J]. Chin J Infect Dis, 2023, 41(1): 3-28. DOI: 10.3760/cma.j.cn311365-20230220-00050. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41(1): 3-28. DOI: 10.3760/cma.j.cn311365-20230220-00050.